GVHD
Advertisement
Learn how oral dysbiosis correlates with exacerbated cGVHD in patients after receiving hematopoietic cell transplantation.
Novel agents recently approved by the FDA showed promising responses when combined for treating refractory cGVHD.
Research presented at ASH 2024 highlighted the importance of absolute monocyte counts after transplant.
Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ...
A study presented at the 2024 ASH Annual Meeting suggests that a certain test may predict GI issues caused by GVHD.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
The study highlighted that adding abatacept to CNI/MTX-based GVHD prophylaxis showed durable central outcomes post-HCT.
Kirk R. Schultz, MD, FCAHS, explains that multiple strategies for GVHD prevention and preemption are under investigation.
Risk factors for GVHD and its severity differ by donor type following allogeneic SCT with post-transplant PTCy prophylaxis.
Patients with pulmonary comorbidities and a history of smoking are at increased risk for chronic GVHD.
Piyanuch Kongtim, MD, PhD, shares insights from work she presented at the 2024 ASH Annual Meeting.
Irwin Walker, MBBS, joined Cancer Nursing Today at ASH 2024 to share his insights on the pilot trial and the next steps.
Patient-reported outcomes increased the risk of health care utilization and HCT-related complications, like GVHD, post HCT.
Chronic GVHD is less frequent in children than in adults, but its frequency has come down much more significantly in adults.
Noah Merin, MD, PhD, explains how the GVHD prophylaxis method has changed outcomes and shares nursing implications at ASH.
The study, presented at ASH 2024, showed that none of the patients experienced grade 3-4 GVHD.
Metabolite profiles may be promising as predictive biomarkers for clinical outcomes in patients post-HSCT at risk of GVHD.
A study presented at ASH evaluated GVHD and NRM outcomes in patients who received allogeneic transplant after CAR-T.
Research presented at ASH showed that baseline fatigue and depression were associated with acute GVHD.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.